This potential sensitivity underscores the promise of small molecule inhibitors selectively targeting POLE exonuclease activity, which could significantly enhance the therapeutic efficiency of anti-PD-1/PD-L1 treatment in carcinomas with WT POLE. Here, POLE is linked to carcinoma.